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Background: Schizophrenia is a complex psychiatric disorder with a lifetime morbidity rate
of 0.5–1.0%. The pathophysiology of schizophrenia still remains obscure. Accumulating
evidence indicates that DNA methylation, which is the addition of a methyl group to
the cytosine in a CpG dinucleotide, might play an important role in the pathogenesis of
schizophrenia.
Methods: To gain further insight into the molecular mechanisms underlying schizophrenia,
a genome-wide DNA methylation profiling (27,578 CpG dinucleotides spanning 14,495
genes) of the human dorsolateral prefrontal cortex (DLPFC) was conducted in
a large cohort (n = 216) of well characterized specimens from individuals with
schizophrenia and non-psychiatric controls, combined with an analysis of genetic variance
at ∼880,000 SNPs.
Results: Aberrant DNA methylation in schizophrenia was identified at 107 CpG sites at 5%
Bonferroni correction (p < 1.99 × 10−6). Of these significantly altered sites, hyper-DNA
methylation was observed at 79 sites (73.8%), mostly in the CpG islands (CGIs) and in the
regions flanking CGIs (CGI: 31 sites; CGI shore: 35 sites; CGI shelf: 3 sites). Furthermore,
a large number of cis-methylation quantitative trait loci (mQTL) were identified, including
associations with risk SNPs implicated in schizophrenia.
Conclusions: These results suggest that altered DNAmethylation might be involved in the
pathophysiology and/or treatment of schizophrenia, and that a combination of epigenetic
and genetic approaches will be useful to understanding the molecular mechanism of this
complex disorder.
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INTRODUCTION
Schizophrenia is a complex psychiatric disorder with a lifetime
morbidity rate of 0.5–1.0%. Accumulating evidence indicates that
DNA methylation, which is the addition of a methyl group to the
cytosine in a CpG dinucleotide, might play an important role in
the pathogenesis of schizophrenia. For example, L-methionine,
a precursor of S-adenosylmethionine, which donates its methyl
group to various acceptors, exacerbates the psychotic symptoms
of schizophrenia patients (Pollin et al., 1961; Cohen et al., 1974).
L-methionine-treated mice exhibited increased DNAmethylation
that was accompanied by decreasedmRNA levels of specific genes,
and by behavioral changes similar to those seen in schizophre-
nia (Tremolizzo et al., 2002, 2005). In addition, an increased
mRNA expression of DNA methyl-transferases (DNMT1 and
DNMT3a) has been observed in schizophrenia (Veldic et al.,
2004, 2005; Ruzicka et al., 2007; Zhubi et al., 2009). Furthermore,
aberrant DNA methylation in brains of patients with schizophre-
nia (Abdolmaleky et al., 2005, 2006, 2011; Grayson et al., 2005;
Iwamoto et al., 2005; Tamura et al., 2007; Mill et al., 2008;
Tolosa et al., 2010; Wockner et al., 2014) and the associations
of different DNA methylation patterns with phenotypic discor-
dance of schizophrenia between twins (Petronis et al., 2003;
Dempster et al., 2011; Kinoshita et al., 2013) have been reported.
However, the sample sizes in these previous epigenetic studies of
schizophrenia were relatively small and the number of CpG sites
interrogated was limited.
Tissue-specific differences in DNA methylation have been
extensively documented (Christensen et al., 2009; Davies et al.,
2012). Thus, since schizophrenia is a brain disorder, it is par-
ticularly important to examine the epigenetic modifications of
the brains in patients with schizophrenia, rather than in the
peripheral tissues. In this study, we conducted a genome-wide
DNA methylation profiling (27,578 CpG dinucleotides spanning
14,495 genes) of the dorsolateral prefrontal cortex (DLPFC), a
brain region implicated in cognition and schizophrenia, in a
large cohort of well characterized specimens (106 patients with
schizophrenia and 110 non-psychiatric controls), and identified
genes whose methylation levels differed between patients with
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schizophrenia and controls. We also conducted a genome-wide
association analysis of single nucleotide polymorphisms (SNPs)
with DNA methylation in the same samples, and revealed a
large number of cis-methylation quantitative trait loci (mQTL),
including associations with risk SNPs implicated in schizophre-
nia. These results will add further insight into the molecular
mechanisms of the pathophysiology of schizophrenia.
MATERIALS AND METHODS
HUMAN POSTMORTEM BRAIN TISSUE COLLECTION
Postmortem human brains (n = 185) were collected through the
Offices of the Chief Medical Examiners of Washington, DC and
Virginia, Northern District by the Section on Neuropathology at
the Clinical Brain Disorders Branch, National Institute of Mental
Health, National Institutes of Health (NIH), according to the NIH
Institutional Review Board (IRB) and ethical guidelines under
protocol #90-M-0142. Thirty one additional postmortem human
brain specimens were collected through the Stanley Medical
Research Institute. Clinical characterization, neuropathological
screening, toxicological analyses, and dissections of the DLPFC
were performed as previously described (Lipska et al., 2006).
Briefly, all patients met DSM-IV criteria for a lifetime Axis I
diagnosis of schizophrenia (n = 97) or schizoaffective disorder
(n = 9) according to DSM-IV, and controls were defined as those
individuals with no history of significant psychological problems
or psychological care, psychiatric admissions, or drug detoxifi-
cation and with no known history of psychiatric symptoms or
substance abuse, as determined by both telephone screening and
medical examiner documentation as well as negative toxicology
results. Demographic data for these samples are summarized in
Supplementary Table S1.
GENOTYPING METHODS
SNP genotyping with Human1M-Duo V3 BeadChips (Illumina
Inc., San Diego, CA) was carried out according to the manufac-
turer’s instructions, using DNA extracted from cerebellar tissue.
Genotype data were analyzed using the Genotyping Analysis
Module within the BeadStudio software (Illumina Inc.). For
data analysis, 875,511 SNPs with missing calls <2%, Hardy–
Weinberg equilibrium p-values≥0.001, and minor allele frequen-
cies ≥0.015 were used, from among a total of 1,199,187 SNPs.
METHYLATION METHODS
Genomic DNA was extracted from 100mg of pulverized DLPFC
tissue using the phenol-chloroform method. Bisulfite conver-
sion of 600 ng genomic DNA was performed using the EZ DNA
methylation kit (Zymo Research). Methylation of DNA extracted
from the DLPFC was assessed according to the manufacturer’s
instructions using Infinium HumanMethylation27 BeadChips
(Illumina Inc.). Quantitative measurements of DNA methylation
were determined for 27,578 CpG dinucleotides spanning 14,495
genes. CpG sites were selected by Illumina Inc. in the gene pro-
moter regions, within 1 kb upstream and 500 bases downstream
of the transcription start sites (TSSs). CGIs, CGI shores (0–2 kb
from CGIs), CGI shelves (2–4 kb from CGIs) were defined as in
a previous paper (Irizarry et al., 2009). DNA methylation data
were analyzed using the Methylation Analysis Module within
the BeadStudio software (Illumina Inc.). Normalization was car-
ried out using lumiMethyN function from lumi package. The
DNA methylation level of each CpG site was calculated as an
M-value, which is the log2 ratio of methylated and unmethy-
lated probe intensities. The technical schemes of this array have
been described in detail in a previously published paper (Bibikova
et al., 2009). Qualified CpG sites used in statistical analyses were
defined as follows: (1) detected in 80% subjects, (2) excluded
sex chromosome, (3) excluded 100% non-specific probes that
completely match to other sequences, (4) excluded probes with
SNPs at the CpG site with minor allele frequency MAF > 0.1%.
A list of potential non-specific probes and polymorphic probes
of Illumina Human 27K Methylation Array can be downloaded
at http://braincloud.jhmi.edu/downloads.htm. The final data set
included 25,156 CpG sites (Supplementary Table S2). To ensure
data reproducibility, 10 samples were analyzed in duplicates start-
ing from the bisulfite conversion step, and high reproducibility
was observed (r2 ranged from 0.9973 to 0.9921). For validation,
we used 92 samples from the current study and measured methy-
lation status at 34 CpG sites using Illumina custom GoldenGate
platform. The CpG site positions for the probes were exactly the
same as in the Infinium arrays. The correlation between the data
from the two platforms was very high (r2 = 0.79) as described in
Numata et al. (2012).
STATISTICAL METHODS
Surrogate variable analysis was used to account for known and
unknown factors affecting the data, including batch effects (Leek
and Storey, 2007). A general linear model was then used to
examine the effects of the primary variables: age, sex, race, and
diagnosis as well as the surrogate variables. The residuals from
multiple regression analysis were used to analyze associations
with SNP genotypes by PLINK (Purcell et al., 2007). Outliers were
identified using Grubb’s test and removed from further analysis.
SNPs within 1 Mb of a CpG site were defined as cis-SNPs, as in
previous studies (Gibbs et al., 2010; Zhang et al., 2010; Numata
et al., 2012). In these analyses, Bonferroni correction for multiple
testing was applied at the 0.05 level.
TRANSCRIPTION METHODS
For correlations between DNA methylation and expression, we
utilized previously published expression data from the DLPFC
obtained using Human HT-12_V3 Illumina BeadArrays as
described in detail in Ye et al. (2012). Only probes expressed above
the background (p < 0.05) in at least 80% of subjects were ana-
lyzed. Normalization was carried out using lumi R package. The
ComBat R package was used for batch effects. Surrogate variable
analysis was used with SVA R package with age, sex, race, and
diagnosis as primary variables. A step-wise model selection was
used for each gene, and a multiple linear regression analysis was
performed with the best fit model.
RESULTS
DIAGNOSTIC DIFFERENCES IN DNA METHYLATION
Significant diagnostic differences in DNA methylation were
observed at 107 CpG sites at 5 % Bonferroni correction (p <
1.99 × 10−6, Supplementary Table S3) out of a total 25,156 CpG
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FIGURE 1 | Diagnostic differences in DNA methylation. The x axis
represents magnitude of a change (beta value) between controls and
schizophrenia subjects calculated by linear regression analysis in 216
samples. The y axis represents −log 10 p-values. Each dot represents an
individual CpG site (a total of 25,156 CpG sites). Red dots represent 107
CpG sites that showed significant diagnostic differences between
schizophrenic subjects and controls (5% Bonferroni correction). Magnitude
of change >0 corresponds to higher methylation in patients with
schizophrenia than in controls, whereas magnitude of change <0
corresponds to lower methylation in patients with schizophrenia than in
controls. Of these 107 CpG sites, 79 sites (73.8%) demonstrated higher
methylation in patients with schizophrenia than in controls.
sites examined. Of these 107 CpG sites, 79 sites (73.8%) demon-
strated higher DNAmethylation in schizophrenia than in controls
(Figure 1). Examples of diagnostic-biased genes include GRIA4
(glutamate receptor, inotropic, AMPA4) and ASTN2 (astro-
tactin 2) (Figure 2), both of these genes have been previously
implicated in schizophrenia (Makino et al., 2003; Vrijenhoek
et al., 2008; Wang et al., 2010). When the 79 sites hypermethy-
lated in schizophrenia were classified into four categories (CGI,
CGI shore, CGI shelf, and others), most of them (87.3%) were
located in the CGIs and in the regions flanking CGIs (CGI: 31
sites; CGI shore: 35 sites; CGI shelf: 3 sites; others: 9 sites). In
contrast, when 28 sites, which demonstrated significantly reduced
DNA methylation in schizophrenia, were classified into the same
four categories, most of them (85.7%) were located not in or near
CGIs but outside CGIs (i.e., others: 23 sites; CGI: 1 site; CGI
shore: 3 sites; CGI shelf: 1). There was no effect of smoking on
DNA methylation in any group.
THE mQTL ANALYSIS
A genome-wide association analysis of SNPs with DNA methyla-
tion was conducted in the combined cohort of controls and cases
to identify mQTL, as has been done in other previous QTL stud-
ies (Liu et al., 2010; Zhang et al., 2010; Gamazon et al., 2013).
In the cis-analysis (cis defined as within 1 Mb of a CpG site),
36,366 SNP-CpG pairs were significantly correlated (Bonferroni
corrected p < 0.05) (Supplementary Table S4). When the asso-
ciation analysis was performed in the subjects with schizophre-
nia and controls separately, 89.7% of cis-associations from the
subjects with schizophrenia and 89.5% of cis-associations from
controls were found in the analysis of the combined cohort
(Supplementary Table S5).
Among these significant cis-associations in the combined
cohort, we found SNPs that have been previously associated with
increased risk for schizophrenia. For instance, as shown in the
recent study (Smith et al., 2013), a frequent promoter variant
rs6311 of the HTR2A [5-hydroxytryptamine (serotonin) receptor
2A] gene, widely implicated in human neuropsychiatric disor-
ders and significant in the meta analysis in the Schizophrenia
Gene database (Allen et al., 2008), decreases usage of an upstream
transcription site encoding a longer 5′UTR with greater transla-
tion efficiency. Our data show that the A allele, which increases
risk for schizophrenia, is associated with higher methylation
at the HTR2A locus cg00308665 (Bonferroni corrected p =
3.02 × 10−16). These data suggest a possible interplay between
higher CpGmethylation and repressed expression of the extended
5′UTR and might offer a molecular mechanism for the statistical
association of rs6311 with mental disorders.
Two other SNPs, rs13219354 (PRSS16) and rs3747600
(C16orf5), with significant mQTLs in our analysis, were found
among the top 18 markers in another large genome-wide asso-
ciation study of schizophrenia (a total of 12,945 cases and
34,591 controls) by Stefansson et al. (2009). One SNP, rs7914558
(CNNM2), which was significant after Bonferroni correction
in our analysis, appeared among the top 10 markers in the
mega-analysis combining genome-wide association study data
by the Schizophrenia Psychiatric Gnome-Wide Association Study
Consortium (2011) (a total of 17,836 cases and 33,859 con-
trols). This intronic SNP in CNNM2 (rs7914558) predicted
DNA methylation status at the cg15439196 CpG site in CNNM2
and at cg00035347 site of the neighboring gene, NT5C2 (5′-
nucleotidase, cytosolic II), Bonferroni corrected p = 1.74 × 10−2
and 6.05 × 10−22, respectively), Figure 3.
DNA METHYLATION CORRELATES WITH EXPRESSION OF A SUBSET
OF GENES
To interrogate relationships between DNA methylation and tran-
scription, we correlated (Pearson’s correlation)methylation status
at CpG loci in gene promoters with expression of all probes on the
array corresponding to the same gene using genome-wide tran-
scriptional profiling data of the DLPFC from the same subjects
(Ye et al., 2012) (all pairs were within 100 kb, a total number of
such correlations was 107,031). Overall, across all CpG sites, there
was poor correlation with expression.We identified only 86 corre-
lations significant after Bonferroni correction (p < 4.63 × 10−7),
of which 73 (84.9%) were negative (Supplementary Table S6).
Of particular interest is GNMT (glycine N-methyltransferase)
with high negative correlation between DNA methylation and
expression (r = −0.42, p = 4.5 × 10−10). GNMT catalyzes the
synthesis of sarcosine from glycine using S-adenosylmethionine
as the methyl-donor in one carbon metabolic pathway, and
Gnmt−/− mice have shown dysregulation of DNA methyltrans-
ferases (DNMT1 and Dnmt3a), ErbB (Nrg1 and ErbB4), and
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FIGURE 2 | Diagnostic differences in the DNA methylation levels of
GRIA4 and ASTN2. The x axis represents diagnostic groups (control
and schizophrenia), and the y axis represents DNA methylation levels
(log2 ratio of methylated and unmethylated probe intensities). The
lines in the bar graph indicate the median, and the bars (whiskers)
represent the minimum and maximum values after the removal of
the outliers. The CpG sites of the GRIA4 (cg19343464) and ASTN2
(cg00121640) showed significantly higher DNA methylation in patients
with schizophrenia than in controls (p = 3.55 × 10−7 and
p = 1.09 × 10−6).
mTOR (Akt2, S6, S6k1, and S6k2) in the cortex, as well as
abnormal behaviors associated with schizophrenia (Yang et al.,
2012).
DISCUSSION
We identified over one hundred CpG sites with aberrant DNA
methylation in schizophrenia in this genome-wide DNA methy-
lation profiling study performed in a large cohort of 106 patients
with schizophrenia and 110 non-psychiatric controls. To date, 11
DNAmethylation studies were conducted on schizophrenia using
postmortem brains, but the sample sizes of these studies were
relatively small (∼35 patients with schizophrenia) (Abdolmaleky
et al., 2005, 2006, 2011; Grayson et al., 2005; Iwamoto et al., 2005;
Dempster et al., 2006; Tamura et al., 2007;Mill et al., 2008; Tochigi
et al., 2008; Tolosa et al., 2010; Wockner et al., 2014).
Our study demonstrated that altered DNA methylation in
schizophrenia was more likely to show a pattern of hyper- DNA
methylation, and that it occurred at CpG sites not only in the
CGIs but also in the CGI shores. These findings are in agree-
ment with a recent genome-wide DNA methylation study using
the leukocytes of patients with schizophrenia (Kinoshita et al.,
2013). In line with our results, an increased mRNA expressions of
DNA methyl-transferases has been found in post-mortem brains
of schizophrenia (Veldic et al., 2004, 2005; Ruzicka et al., 2007;
Zhubi et al., 2009). We identified a number of genes with signif-
icant epigenetic alterations in schizophrenia, and some of these
genes, such asGRIA4,ASTN2, andDCDC2 (doublecortin domain
containing 2) with increased DNA methylation at particular CpG
loci, have previously been implicated in schizophrenia. For exam-
ple, genetic variations in GRIA4, a subunit of AMPA receptor that
mediates fast synaptic excitatory neurotransmission, have been
associated with schizophrenia and antipsychotic responses in
patients. Moreover, GRIA4-deficient mice exhibit schizophrenia-
related phenotypes (Makino et al., 2003; Lavedan et al., 2009;
Sagata et al., 2010; Fijal et al., 2012). ASTN2 is expressed at high
levels in migrating cerebellar granule neurons at developmental
stages when glial-guided migration occurs (Wilson et al., 2010).
SNPs in this gene have been associated with schizophrenia and
metabolic side effects of antipsychotic drugs, as well as with
autism, attention deficit hyperactivity disorder, hippocampal vol-
ume, and cognition (Lesch et al., 2008; Vrijenhoek et al., 2008;
Glessner et al., 2009; Wang et al., 2010; Adkins et al., 2011; Lionel
et al., 2011; Bis et al., 2012). DCDC2 gene is located on chro-
mosome 6p22.1, a region with strong evidence of linkage with
schizophrenia (Shi et al., 2009). This gene has been also identified
as a candidate gene for reading disability, and implicated in neu-
ronal migration (Meng et al., 2005). SNPs in this gene have been
associated with cortical graymatter and resting state fMRI activity
in language-related brain regions in patients with schizophrenia
(Jamadar et al., 2011, 2013).
We did not find changes in methylation status for a num-
ber of genes reported in the previous postmortem brain stud-
ies of DNA methylation based on candidate gene approaches.
For instance hyper- DNA methylation of RELN, SOX10 [SRY
(sex determining region Y)-box 10], FOXP2 (forkhead box P2),
and HTR2A as well as hypo- DNA methylation of MB-COMT
(membrane-bound catechol-O-methyltransferase) and HTR2A
have been reported in schizophrenia (Grayson et al., 2005;
Iwamoto et al., 2005; Abdolmaleky et al., 2006, 2011; Tolosa et al.,
2010). Although Infinium HumanMethylation27 BeadChips cov-
ered these five genes, the exact locations of CpG sites were
different from those in the previous studies. This may explain
discrepancies between our results and those in the previous
studies. When we compared our data with the previous genome-
wide DNAmethylation study using CpG-islandmicroarrays (Mill
et al., 2008), we found one common gene, MRPS14 (mitochon-
drial ribosomal protein S14), which showed significantly higher-
DNA methylation changes in schizophrenia in both studies. This
result suggests that there may be changes in mitochondrial func-
tion in schizophrenia (Anglin et al., 2012). Recently, Wockner
et al. identified 4641 probes corresponding to 2929 genes which
were found to be differentially methylated between diagnosis in
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FIGURE 3 | Cis-association of a SNP with DNA methylation. The x axis
represents three genotypes of each SNP (1/1 red, 1/2 green, and 2/2 blue,
where 1 = A or T allele and 2 = G or C allele), and the y axis represents
DNA methylation levels. The lines in the bar graph indicate the median, and
the bars (whiskers) represent the minimum and maximum values after the
removal of the outliers. rs7914558 was associated with DNA methylation
status at cg15439196 in the CNNM2 gene (Bonferroni corrected
p = 1.74 × 10−2).
frontal cortex post-mortem brain tissue from 24 patients with
schizophrenia and 24 unaffected controls using Illumina Infinium
HumanMethylation450 BeadChip (Wockner et al., 2014). Of
4641 probes they identified, 198 common probes were used
between Infinium HumanMethylation27 BeadChip and Infinium
HumanMethylation450 BeadChip. Of 198 probes, we found one
common probe between studies in the FAM5C (family with
sequence similarity 5, member C) gene, also known as BRINP3,
which showed significantly higher- DNA methylation changes
in schizophrenia in both studies. BRINP family is developmen-
tally regulated neural-specific proteins (Kawano et al., 2004), and
BRINP3 is related to proliferation and migration (Shorts-Cary
et al., 2007).
Finally, this study revealed a large number of cis-mQTLs
in the human prefrontal cortex, including risk SNPs associated
with schizophrenia in recent genome-wide association studies
(Stefansson et al., 2009; Schizophrenia Psychiatric Gnome-Wide
Association Study Consortium, 2011). This data set can be useful
to reveal potential roles of previously identified risk SNPs associ-
ated with schizophrenia as well as discover novel target genes in
schizophrenia.
There are several limitations to the present study. First, the
coverage of transcriptome by mRNA expression probes and the
coverage of methylome by CpG site probes were limited in
this study. Especially, more comprehensive methylome mapping,
including CpG sites outside CpG islands and intragenic regions
will be needed to do a broader analysis of DNA methylome in
schizophrenia. We have already initiated such a study. Second,
we used genomic DNA extracted from the heterogeneous mix-
ture of various cell types. However, cell type-specific variations
in DNA methylation have been documented (Iwamoto et al.,
2011) and thus cell type-specific methylome mapping should be
performed. Third, we did not investigate histone modifications
which are also known to play a role in regulating gene expres-
sion (Berger, 2007). Moreover, it is not possible to differentiate
methylation from 5-hydroxymethylation of cytosine which also
plays a critical role in gene regulation (Bhutani et al., 2011).
Finally, it is possible that despite our efforts to remove confound-
ing variables, batch effects and other factors, including smoking
and body mass index (Breitling et al., 2011; Dick et al., 2014)
might have contributed to the observed differences between the
diagnostic groups.
Despite these limitations, our results suggest that altered DNA
methylation might be involved in the pathophysiology and/or
treatment of schizophrenia, and that a combination of epige-
netic and genetic approaches will be useful to understanding the
molecular mechanism of this complex disease.
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